Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 8/20 | 0.54 |
| ▸ | CA12 | O43570 | 7/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.54 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482729 | 0.90 | TDP1 (0.65) | TDP1CA9CA12CA2RAB9A | |
| SCHEMBL2057514 | 0.89 | CA9 (0.66) | TDP1CA9CA12CA2RAB9A | |
| SCHEMBL11598927 | 0.85 | TDP1 (0.58) | TDP1CA9CA12CA2RAB9A | |
| SCHEMBL3482749 | 0.85 | LMNA (0.57) | TDP1RAB9ASMN1; SMN2ESR1LMNA | |
| SCHEMBL9657376 | 0.85 | APOBEC3G (0.52) | TDP1SMN1; SMN2LMNAHTTCNR2 | |
| SCHEMBL13911246 | 0.81 | GAA (0.67) | CA9CA12GAANPSR1CNR2 | |
| SCHEMBL13900674 | 0.81 | TDP1 (0.53) | TDP1CA9CA12CA2RAB9A | |
| SCHEMBL7230825 | 0.81 | CA9 (0.61) | TDP1CA9CA12CA2RAB9A | |
| SCHEMBL16442202 | 0.81 | CA9 (0.57) | TDP1CA9CA12CA2RAB9A | |
| SCHEMBL28583355 | 0.80 | CA9 (0.53) | TDP1CA9CA12CA2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | TDP1 4874/4885CA9 2242/4885CA12 3635/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | TDP1 4853/4885CA9 1576/4885CA12 3810/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | TDP1 4853/4885CA9 1576/4885CA12 3810/4885 |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | SLC5A1, SLC5A2, SLC2A9 | TDP1 3868/4885CA9 240/4885CA12 501/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | TDP1 4853/4885CA9 1576/4885CA12 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.